TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Abuse potential
Endpoint domain: Adverse events/effects
Primary endpoint: LV myocardial remodeling parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: distance of the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: support normal birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IPSS-Q8 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: GP satisfaction with QPT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified CEAP clinical score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgetic tablet intake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: vitality subscale of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma t-PA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bradykinin-induced vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality-Adjusted Survival (QAS) time
Endpoint domain: Mortality/survival
Primary endpoint: incidence of VP complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wake after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased responsivity of brain regions involved in face and emotion processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sP-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Secretion clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cst (compliance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C(eff) (effective compliance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sEMG of Vastus Medialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vigor subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Economic hardship
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Exposure to Adverse Childhood Experiences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: risk of stroke during or within 24 h after air travel
Endpoint domain: Mortality/survival
Primary endpoint: quadriceps CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: opioid abstinence rates
Endpoint domain: Mortality/survival
Primary endpoint: relapse outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of neutrophil elastase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of DAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bioequivalence of metformin hydrochloride formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐t and Cmax within acceptance range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emotional fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: total mean estimated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major haemorrhage (>1000 ml)
Endpoint domain: Adverse events/effects
Primary endpoint: need for additional uterotonic agent
Endpoint domain: Adverse events/effects
Primary endpoint: Parasitological or clinical treatment failure (TF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemifield MD values of B/Y perimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of RNFL loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall clinical response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 anemia and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean total FSFI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: gingival microleakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new Gd+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neointimal coverage grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADCS-CGIC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: microscopically detectable parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: H. pylori eradication success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete three chair-rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SFer concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in rHuEPO dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lean Body Mass Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Passive ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharmacokinetic characteristics of DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of DM
Endpoint domain: Adverse events/effects
Primary endpoint: Serum androstenedione levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary androgen metabolites excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Brief Psychiatric Rating Scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sense of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: met needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consumption of sugar-sweetened beverages and high-fat foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clearance of HBV-DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ins-T(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ins-AUC(0-120)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved physical health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced mental and emotional state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OC to CTX ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CETP activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-C increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of total eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced expiratory volume one second (FEV(1.0))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Detection of HCV positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lowest oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive patient-reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in glycaemic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of HbA1c increase of ≥ 0.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HOMA-2β values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HCMV-DNA presence in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consumption of rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of CD3+ CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sIL-2R production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean gradient across the left ventricular outflow tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of suicide risk
Endpoint domain: Mortality/survival
Primary endpoint: Median plasma values of BNP at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collagen-induced platelet-aggregability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained effects on cocaine and alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of Lean Mass (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Loss of Fat Mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prosthesis/implant failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical signs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of neck symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self‐experienced working ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Residual flow to the infarct zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrent stroke rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Patient satisfaction with pain management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient preference for ibandronate regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convenience of ibandronate regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CML levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CML levels in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adaptation to support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceptions of benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceptions of barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average pitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of acute renal insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increase in serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Levels of UAER, 132‐MG in serum and in urine, alpha1‐MG in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total score of syndrome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fracture risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean growth velocity of the lower leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of non-vertebral fragility fractures (NVFFx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Risk of clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Risk of pooled new and worsened vertebral fractures (VFx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disease Management (DM)
Endpoint domain: Adverse events/effects
Primary endpoint: coping with pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of remaining autonomous
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Serum concentrations of TXB(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Perception of the biopsychosocial message
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disability risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quadriceps function recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP levels after PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-traumatic stress disorder scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Six-minutes walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentially methylated regions (DMRs) at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus Handicap Inventory (THI) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratings of loudness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of tinnitus after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphological changes in the peritoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in TRL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic epithelial cell proliferation (LI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of abscess
Endpoint domain: Adverse events/effects
Primary endpoint: Dyspareunia after procedure
Endpoint domain: Adverse events/effects
Primary endpoint: FSFI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PANSS-EC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum P-wave duration (Pmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: objective performance measures of cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: long-term relief of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve [0-inf]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DCTT (Duodenal Contraction Transit Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean duration of complete migrating motor complex (MMC) cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antral motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prognostic Inflammatory and Nutritional Index (PINI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deep open target fissure healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Xerosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NRS level at 12 hr and 24 hr after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative amount of transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overdenture survival
Endpoint domain: Mortality/survival
Primary endpoint: pyretolysis effect initiating time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for body temperature recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rash subside time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Functional recovery in WM segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak SRs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum testosterone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plantar pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contact area in the forefoot area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on map-related quiz questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Failure to obtain CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach peak plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of defecations per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in SOFA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dermal Blood Flow (DBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of all stroke events
Endpoint domain: Mortality/survival
Primary endpoint: SSS-8 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CESDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative eyelid edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of painkillers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of cerebrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Plaque effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of TC, TG, LDL-C, and FIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge of anaphylaxis treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-rated unmet need
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IL-2 serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete response after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion free at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes